FMP
TransCode Therapeutics, Inc.
RNAZ
NASDAQ
TransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs and diagnostics for treating and identifying metastatic disease. Its lead therapeutic candidate, TTX-MC138, is a preclinical stage product for the treatment of metastatic cancer. The company's products in preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. Its cancer agnostic programs comprise TTX-RIGA, an RNAbased agonist of the RIG-I-driven immune response in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines meant to activate cytotoxic immune responses against tumor cells. The company was incorporated in 2016 and is based in Boston, Massachusetts.
0.311 USD
0.0109 (3.51%)
RNAZ Financial Statements
Year
2024
2023
2022
2021
Current Assets
7.09M
4.46M
7.38M
22.73M
Cash & Short Term Investments
5.81M
2.77M
4.97M
20.83M
Cash And Cash Equivalents
5.81M
2.77M
4.97M
20.83M
Short Term Investments
0
0
9.41
9.41
Net Receivables
0
0
360.23k
0
Inventory
0
0
554.33k
0
Other Current Assets
1.28M
1.14M
1.5M
1.84M
Non-Current Assets
201.16k
714.26k
208.58k
206.27k
Property, Plant & Equipment
89.31k
602.4k
208.58k
206.27k
Goodwill And Intangible Assets
0
0
0
0
Goodwill
0
0
0
0
Intangible Assets
0
0
0
0
Long Term Investments
0
0
0
0
Tax Assets
0
0
0
0
Other Non-Current Assets
111.86k
111.86k
-0
-0
Other Assets
0
0
-0
0
Total Assets
7.29M
5.17M
7.59M
22.94M
-
-
-
-
Current Liabilities
2.77M
3.49M
4.35M
2.53M
Accounts Payable
0
0
4.35M
2.02M
Short Term Debt
38.29k
0
0
0
Tax Payables
0
0
0
0
Deferred Revenue
25.41k
27.06k
0
30.53k
Other Current Liabilities
2.71M
0
-4.35M
-2.02M
Total Current Liabilities
2.77M
3.49M
4.35M
2.53M
Total Non-Current Liabilities
6.54M
38.29k
4.35M
0
Long-Term Debt
0
0
0
0
Deferred Revenue
0
0
0
0
Deferred Taxes Liabilities
0
0
0
0
Other Non Current liabilities
6.54M
0
0
0
Total Liabilities
9.31M
3.53M
4.35M
2.53M
Other Liabilities
0
0
-4.35M
0
Stockholders Equity
-2.02M
1.64M
3.24M
20.4M
Common Stock
103
63
1.3k
1.29k
Retained Earnings
-63.2M
-46.42M
-27.87M
-10.31M
Accumulated Other Comprehensive Income/Loss
0
0
0
0
Other Shareholders Equity
0
0
1.3k
0
Total Liabilities and Stockholders Equity
7.29M
5.17M
7.59M
22.94M
All figures are in USD.
